A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19

Cristina Valencia-Sanchez; Dean M. Wingerchuk

doi:10.1016/j.msard.2020.102182

A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19

Cristina Valencia-Sanchez, Dean M. Wingerchuk

Neurology

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background: Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. Methods: Case report Results: We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab. Conclusion: This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.

Original language	English (US)
Article number	102182
Journal	Multiple Sclerosis and Related Disorders
Volume	42
DOIs	https://doi.org/10.1016/j.msard.2020.102182
State	Published - Jul 2020

Keywords

COVID-19
Fingolimod
Multiple sclerosis
Tocilizumab

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.msard.2020.102182

Fingerprint Dive into the research topics of 'A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19'. Together they form a unique fingerprint.

Cite this

@article{72d2c8b8748743b0aaf9301c97edb2a8,

title = "A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19",

abstract = "Background: Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. Methods: Case report Results: We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab. Conclusion: This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.",

keywords = "COVID-19, Fingolimod, Multiple sclerosis, Tocilizumab",

author = "Cristina Valencia-Sanchez and Wingerchuk, {Dean M.}",

year = "2020",

month = jul,

doi = "10.1016/j.msard.2020.102182",

language = "English (US)",

volume = "42",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier",

}

TY - JOUR

T1 - A fine balance

T2 - Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19

AU - Valencia-Sanchez, Cristina

AU - Wingerchuk, Dean M.

PY - 2020/7

Y1 - 2020/7

N2 - Background: Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. Methods: Case report Results: We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab. Conclusion: This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.

AB - Background: Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. Methods: Case report Results: We report a fingolimod-treated MS patient who developed severe COVID-19 but recovered after treatment with tocilizumab. Conclusion: This report suggests that a brief course of tocilizumab for the treatment of severe COVID-19 may be effective while not aggravating pre-existing MS.

KW - COVID-19

KW - Fingolimod

KW - Multiple sclerosis

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85084416583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85084416583&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2020.102182

DO - 10.1016/j.msard.2020.102182

M3 - Article

C2 - 32416330

AN - SCOPUS:85084416583

VL - 42

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

M1 - 102182

ER -